

ONCOTYPE MAP™ PAN-CANCER TISSUE TEST


RAPID COMPREHENSIVE GENOMIC PROFILING TO AID THERAPY SELECTION

Every day matters. Why wait?

Oncotype MAP Pan-Cancer Tissue test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, relapsed or recurrent cancer. The test identifies actionable genomic alterations within 3-5 business days** to guide timely treatment decisions, usually before the next follow-up visit.

Utilizing next generation sequencing (NGS) and a broad array of immunohistochemical (IHC) stains and panels, the Oncotype MAP Pan-Cancer Tissue test identifies clinically-relevant genomic alterations from minimal amounts of tissue. The NGS test can be run on patient specimens as small as 3 mm² of tissue with ≥15% tumor content (20% optimal for MSI), allowing you to identify appropriate patient therapy based on tumor characteristics.

Results are provided in an easy-to-interpret report with NCCN® actionable indications for therapy, along with potential evidence-based therapies and clinical trials, to guide treatment options for a breadth of solid tumor types.



Answers you need at the speed your patients deserve



Fast

- Results reported in 3-5 business days
- Quantity Not Sufficient (QNS) results typically reported within 48 hours



Comprehensive

- 257 genes, 11 select fusions
- 21 IHC stains including PD-L1 (22C3, SP142)
- 30+ tumor-specific panels
- Copy number variants, tumor mutation burden, microsatellite instability, and protein expression



Actionable

- 100+ therapies, 45+ combination therapies, 650+ clinical trials
- NCCN Compendium recommendations



Accurate

- Leverages a proprietary method designed for small specimens (3 mm² with tissue with ≥15% tumor content), enabling a low failure rate on both FNA and FFPE samples*
- >99% sensitivity for SNVs and Indels, detection down to ≥7.5% mutant allele frequency (MAF) with >99% specificity*

Oncotype MAP Pan-Cancer Tissue test helps guide therapy selection for today and captures emerging markers that may find their way into guidelines tomorrow.

**Order now for your patients
with solid tumors**

Oncotype MAP™ Pan-Cancer Tissue Test Markers

Immunohistochemistry												
Single IHC Stains		Tumor-Specific Panels										
ALK AR CAIX ER hENT1 HER2 IDO MET MGMT PD1	PD-L1 (22C3) PD-L1 (SP142) PR PTEN ROSI TOPI TP TRKpan TS TUBB3	Anal Carcinoma: PD-L1 (22C3), PD-1, TS, TUBB3 Appendix: HER2, PD-L1 (22C3), TOPI, PTEN Bladder: PD-L1 (22C3), PD-L1 (SP142), hENT1, TUBB3 Bone Cancer: TOPI, MGMT, CAIX, hENT1 Breast: AR, PD-L1(SPI42), PD-L1 (22C3), TP CNS/Brain Cancers: MGMT, CAIX, TUBB3, TOPI Cervical: PD-L1 (22C3), CAIX, hENT1, TOPI Colorectal: HER2, PD-L1 (22C3), TOPI, PTEN, TS Gastric/Esophageal: HER2, PD-L1 (22C3), PTEN, TS GIST: PD-L1 (22C3), MET Head and Neck: PD-L1 (22C3), CAIX, TUBB3, PTEN Head and Neck Salivary Gland: HER2, AR, CAIX, PTEN Hepatobiliary/Cholangiocarcinoma: hENT1, HER2, TP, PD-L1 (22C3) Hepatobiliary/Gallbladder: hENT1, HER2, PD-L1 (22C3), TOPI Hepatobiliary/Hepatocellular: hENT1, PD-L1 (22C3), CAIX, MET Kidney: PD-L1 (22C3), MET, CAIX, hENT1 Melanoma: PD-L1 (22C3), MGMT, PTEN, TUBB3 Mesothelioma: PD-L1 (22C3), TS, hENT1, TUBB3						MMR: MLH1, MSH2, MSH6, PMS2 Neuroendocrine: PD-L1 (22C3), MGMT, PTEN, TP NSCLC: PD-L1 (22C3), ALK, PD-L1 (SP142), PTEN, TS Ovarian: ER, HER2, TOPI, TUBB3 Pancreatic: hENT1, PTEN, TP, TOPI Penile Cancer: PD-L1 (22C3), TP, CAIX, TUBB3 Prostate: AR, PTEN, TUBB3, PD-L1 (22C3) Sarcoma: CAIX, TUBB3, TOPI, MGMT SCLC: PD-L1 (22C3), TOPI, MGMT Small Bowel: TOPI, CAIX, TUBB3, hENT1 Testicular Cancer: PD-L1 (22C3), TUBB3, hENT1 Thyroid: PD-L1 (22C3), ALK, TUBB3, CAIX Thymoma/Thymic Carcinoma: PD-L1 (22C3), TUBB3, hENT1, TS Uterine: PD-L1 (22C3), HER2, MGMT, TUBB3 Uveal Melanoma: PD-L1 (22C3), MGMT, TUBB3 Vulvar Cancer: PD-L1 (22C3), CAIX, TUBB3, hENT1 Other Solid Tumors: PD-L1 (22C3), HER2, TOPI, PTEN, TS				
MMR Panel												
MLH1 MSH2	MSH6 PMS2											
257 Gene NGS Panel												
ABCB1 ABCC1 ABCC2 ABL1 ACVR1 ACVR1B ACVR2A ACVR2B ACVRL1 ADAMTS1 ADAMTS6 ADAMTS9 ADAMTS16 ADAMTS18 ADAMTSL1 AKT1 AKT2 AKT3 ALK AMER1 APC APLNLR AR ARAF	AREG ARID1A ARID1B ARID2 ATM ATR ATRX AURKA AURKB AXIN1 AXL B2M BAP1 BARD1 BCOR BMP6 BMPR1A BMPR1B BNIP3 BRAF BRCA1 BRCA2 BRIP1 BTK	BUB1B CALR CBL CCND1 CCND2 CCND3 CCNE1 CD274 CDK12 CDKN2A CDK1 CDK4 CDK6 CDK12 CDKN2A CHEK1 CHEK2 CHFR CHKA CIC CREBBP CSF1R CTLA4 CTNNB1	CYP19A1 CYP11A1 CYP2D6 CYP3A4 CYSLTR2 DCK DDR2 DICER1 CDA DNMT3A EGFR EMSY EP300 EPCAM EPHA5 EPHA7 EPHA2 ERBB2 ERBB3 ERBB4 ERCC1 ERCC2 ERCC3 ERRF1 ESR1 ESR2	EWSR1 EZH2 FAM175A FANCA FANCC FANCD2 FANCE FANCF FANCG FANCM FAT1 FBXW7 FCGR2A FGD4 FGF3 FGF4 FGFR1 FGFR2 FGFR3 FGFR4 FLT3 FLT4 FOXL2 FUBP1	GAS6 GATA3 GLI1 GNA11 GNAQ GNAS GSTP1 HAMP HDAC2 HGF HNF1A HRAS HSD3B1 IDH1 IDH2 IGF1R IKZF1 IL6R JAK1 JAK2 JAK3 KDM5C KDM6A KDR	KEAP1 KIT KRAS MAF GNAQ MAP2K1 MAP2K2 MAP3K1 MAPK1 MAPK3 MAPKAPK5 MDM2 MDM4 MED12 MEN1 MEN2 MPL MRE11A MSH2 MSH6 MTHFR MTOR MUTYH	MYC MYCN MYO1 NBN NF1 NF2 NFE2L2 NOTCH1 NOTCH2 NOTCH3 NPM1 NRAS NTRK1 NTRK2 NTRK3 PALB2 PBRM1 PDCD1LG2 PDGFRA PDGFRB PIK3CA PIK3CB PIK3CD PIK3CG	PIK3R1 PIM1 PLCB4 PLCG1 PMS2 POLD1 POLE PP2R1A PTCH1 PTEN PTPN11 RAD50 RAD51C RAD51D RAF1 RBI RBM10 RECQL RET RHEB RICTOR RIT1 RNF43 ROSI	RPTOR RRM1 SDHB SDHC SETD2 SF3B1 SMAD1 SMAD2 SMAD4 SMAD5 SMAD9 SMARCA4 SMARCB1 SMO SOCS1 SPOP STAG2 STAT3 STAT5A STAT5B STK11 SUFU TERT-p TGFB1	TGFB2 TGFB3 TGFBFR1 TGFBFR2 TNFAIP3 TNK1 TOP2A TP53 TSC1 TSC2 TSHR TYMS VEGFA VHL WT1 XRCC1 YES1		

Genetic Structures Tested: Single nucleotide variants (SNVs) and insertions/deletions in coding regions of genes listed above; UTRs and splice junctions when actionable (e.g. MET exon 14 skipping and EGFRvIII). MSI; mutation burden (SNV's, insertions, deletions) based on -1 megabase; select fusions involving ALK, BRAF, FGFR1, FGFR2, FGFR3, MET, RET, ROS1, NTRK1, NTRK2, NTRK3 (ETV6); and copy number variants.

Turnaround time is based on when qualified sample is received. Mutation calls may not be available from some regions due to pseudogenes or sequence context. Select IHCs may not be run if already performed within the last six months unless indicated in the notes section. HER2 equivocal by IHC will be reflexed to FISH testing in select tumor types. Reflex testing will exceed standard turnaround time for results. MMR includes the following IHCs: MLH1, MSH2, MSH6, PMS2.



Clinical Laboratory Improvement Amendments



Contact Paradigm Diagnostics/Exact Sciences
 1-866-662-6897 | oncotypemap@exactsciences.com
www.oncotypemap.com

About Exact Sciences

A leading provider of cancer screening and diagnostic tests, Exact Sciences helps people get the answers they need to make more informed decisions across the cancer continuum. Building on the success of the Cologuard® and Oncotype DX® tests, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Through an innovative, rigorous approach, and with the support of visionary collaborators, we're helping advance the fight against cancer.

References:

* Data on file, in-house assay optimization protected by trade-secret/patent regulations.
 † Turnaround time is based on qualified sample receipt.
 ‡ Morris S, Subramanian J, Gel E, Rungger G, Thompson E, Mallery D, et al. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS ONE. (2018); 13(4): e0196556. <https://doi.org/10.1371/journal.pone.0196556>.

NCCN and NCCN Guidelines are trademarks of the National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Oncotype MAP and Oncotype MAP Pan-Cancer Tissue Test are trademarks of Genomic Health, Inc. Exact Sciences is a registered trademark of Exact Sciences Corporation. ©2020 Genomic Health, Inc. All rights reserved. EXS50041_0121

oncotype MAP™
Pan-Cancer Tissue

Paradigm Diagnostics, Inc., a wholly-owned subsidiary of Exact Sciences Corp.
 445 N. 5th Street, Suite 300 | Phoenix, AZ 85004 | 844.232.4719 | exactsciences.com

EXACT
SCIENTES